News|Articles|June 9, 2026

Melanoma Trials You May Have Missed at ASCO 2026

Fact checked by: Ariana Pelosci, Roman Fabbricatore, Justin Mancini

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought meaningful advances across melanoma subtypes and Merkel cell carcinoma, a rare and aggressive skin cancer that continues to generate practice-informing data. Sarah Weiss, MD, spoke with CancerNetwork^® about the findings she found most impactful at the meeting, spanning a landmark efficacy readout in uveal melanoma, a 36-month update in resectable cutaneous melanoma, and 2 data points reshaping how clinicians sequence therapy in Merkel cell carcinoma.